Intraperitoneal chemo-hyperthermia with mitomycin C. Development and in vivo study of tolerability in dogs
Gilly, F.N.; Carry, P.Y.; Sayag, A.C.; Panteix, G.; Brachet, A.; Salle, B.; Baulieux, J.; Peix, J.L.; Braillon, G.
Chirurgie; Memoires de l'Academie de Chirurgie 119(4): 172-174
1993
ISSN/ISBN: 0001-4001 PMID: 7805470 Document Number: 409700
Peritoneal carcinosis is relatively frequent in the clinical course of digestive cancers (48% in cases with invasion of the serous membrane). Despite various therapeutic strategies, prognosis is almost always unfavourable, survival after 6 months is extremely rare. Because of the known in vitro anti-tumour effect of hyperthermia and its chemosensitizing effect during Mitomycine C therapy, we decided to develop a technique based on these two anticancer effects: intraperitoneal hyperthermia and intraperitoneal chemotherapy. Termed CHIP, or chemo-hyperthermia intraperitoneal, this new method could be used for the treatment of peritoneal carcinosis. We report here results of the necessary animal experimentation before such a method could be proposed for human anticancer therapy.